Taysha Gene Therapies, Inc. (TSHA)

Taysha Gene Therapies Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 13, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Cap	1,230	355	331	143	448	1,002
Market Cap Growth	277.32%	7.14%	131.66%	-68.13%	-55.28%	-
Enterprise Value	1,002	274.22	243.84	110.74	359.57	750.94
Last Close Price	4.49	1.73	1.77	2.26	11.65	26.54
PE Ratio	-	-4.81	-1.84	-0.60	-2.51	-7.81
PS Ratio	194.91	42.55	21.42	57.09	-	-
PB Ratio	5.62	4.96	4.42	150.53	4.70	3.99
P/TBV Ratio	6.10	6.05	2.74	104.67	4.60	1.87
P/FCF Ratio	-	-4.35	-4.30	-1.31	-3.39	-32.53
P/OCF Ratio	-	-4.37	-4.53	-1.62	-3.83	-32.61
EV/Sales Ratio	158.74	32.91	15.78	44.26	-	-
EV/EBITDA Ratio	-	-3.04	-3.43	-0.69	-2.08	-17.47
EV/EBIT Ratio	-	-3.00	-3.37	-0.68	-2.08	-17.46
EV/FCF Ratio	-	-3.36	-3.17	-1.02	-2.72	-24.37
Debt / Equity Ratio	0.31	0.86	0.79	61.55	0.66	0
Debt / EBITDA Ratio	-0.67	-0.68	-0.84	-0.36	-0.36	-
Debt / FCF Ratio	-0.79	-0.75	-0.77	-0.54	-0.48	-
Net Debt / Equity Ratio	-1.06	-1.12	-1.16	-33.84	-0.93	-1.00
Net Debt / EBITDA Ratio	2.30	0.89	1.23	0.20	0.51	5.84
Net Debt / FCF Ratio	2.73	0.98	1.13	0.30	0.67	8.15
Asset Turnover	0.03	0.05	0.10	0.01	0	0
Quick Ratio	10.48	5.40	3.99	1.44	2.93	35.24
Current Ratio	10.48	5.42	4.08	1.54	3.08	36.17
Return on Equity (ROE)	-68.79%	-121.94%	-294.04%	-344.67%	-100.68%	-23.88%
Return on Assets (ROA)	-42.83%	-54.91%	-48.45%	-95.49%	-73.29%	-16.61%
Return on Invested Capital (ROIC)	4792.59%	-1863.66%	-1029.91%	-1911.59%	-3159.21%	-8617.64%
Return on Capital Employed (ROCE)	-48.40%	-67.72%	-72.63%	-143.95%	-83.71%	-17.08%
Earnings Yield	-8.12%	-20.81%	-54.24%	-167.26%	-39.83%	-12.81%
FCF Yield	-6.92%	-23.01%	-23.23%	-76.31%	-29.53%	-3.07%
Buyback Yield / Dilution	-24.07%	-21.68%	-42.57%	-37.45%	0.00%	-16.55%

Updated Nov 4, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q